PC
EBS icon

Passport Capital’s Emergent Biosolutions EBS Stock Holding History

Passport Capital’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-7,987
Closed -$202K – 208
2014
Q1 		$202K Buy
+7,987
New +$202K 0.01% 154

Other funds holding EBS

Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Passport Capital's EBS Position: Q2 2014 in Review

Passport Capital sold out of Emergent Biosolutions (EBS) in Q2 2014, closing a stake of 7,987 shares — an estimated $202K sold.

Passport Capital first reported a position in EBS in Q1 2014 and held it in 1 quarter. The position peaked at $202K in Q1 2014. 160 funds tracked by Wall St. Rank hold EBS as of Q2 2014.

  • Passport Capital reported no remaining Emergent Biosolutions position as of Q2 2014 after selling out during the quarter.
  • Passport Capital sold 7,987 Emergent Biosolutions shares in Q2 2014, an estimated $202K.
  • Passport Capital first reported a position in Emergent Biosolutions in Q1 2014 and held it in 1 quarter.
  • Passport Capital's Emergent Biosolutions position peaked at $202K in Q1 2014.
  • 160 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2014.

Based on Passport Capital's 13F filing for Q2 2014, filed 14 Aug 2014.